+

WO2003043569A3 - Trans-10, cis-12 conjugated linoleic acid isomer for the treatment of diseases - Google Patents

Trans-10, cis-12 conjugated linoleic acid isomer for the treatment of diseases Download PDF

Info

Publication number
WO2003043569A3
WO2003043569A3 PCT/US2002/036684 US0236684W WO03043569A3 WO 2003043569 A3 WO2003043569 A3 WO 2003043569A3 US 0236684 W US0236684 W US 0236684W WO 03043569 A3 WO03043569 A3 WO 03043569A3
Authority
WO
WIPO (PCT)
Prior art keywords
cis
linoleic acid
conjugated linoleic
acid isomer
trans
Prior art date
Application number
PCT/US2002/036684
Other languages
French (fr)
Other versions
WO2003043569A2 (en
Inventor
James R Komorowski
Vijaya Juturu
Danielle Greenberg
Original Assignee
Nutrition 21 Inc
James R Komorowski
Vijaya Juturu
Danielle Greenberg
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nutrition 21 Inc, James R Komorowski, Vijaya Juturu, Danielle Greenberg filed Critical Nutrition 21 Inc
Priority to AU2002357729A priority Critical patent/AU2002357729A1/en
Publication of WO2003043569A2 publication Critical patent/WO2003043569A2/en
Publication of WO2003043569A3 publication Critical patent/WO2003043569A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/201—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having one or two double bonds, e.g. oleic, linoleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/28—Compounds containing heavy metals

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Inorganic Chemistry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

A composition for treating insulin- or non-insulin-dependent diabetes, reducing body fat, improving insulin sensitivity, reducing hyperglycemia, and reducing hypercholesterolemia with conjugated linoleic acid isomer trans-10, cis-12 alone, or in combination with any form of a trivalent chromium complex is disclosed. A method of treating a subject suffering from insulin-dependent diabetes by administering a composition that includes conjugated linoleic acid isomer trans-10, cis-12 alone, or in combination with any form of a trivalent chromium complex is similarly provided. The administration of a composition containing an effective dose of conjugated linoleic acid isomer trans-10, cis-12 alone, or in combination with any form of a trivalent chromium complex for the treatment of obesity is likewise provided.
PCT/US2002/036684 2001-11-16 2002-11-12 Trans-10, cis-12 conjugated linoleic acid isomer for the treatment of diseases WO2003043569A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2002357729A AU2002357729A1 (en) 2001-11-16 2002-11-12 Trans-10, cis-12 conjugated linoleic acid isomer for the treatment of diseases

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US33249601P 2001-11-16 2001-11-16
US60/332,496 2001-11-16

Publications (2)

Publication Number Publication Date
WO2003043569A2 WO2003043569A2 (en) 2003-05-30
WO2003043569A3 true WO2003043569A3 (en) 2003-10-30

Family

ID=23298480

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2002/036684 WO2003043569A2 (en) 2001-11-16 2002-11-12 Trans-10, cis-12 conjugated linoleic acid isomer for the treatment of diseases

Country Status (2)

Country Link
AU (1) AU2002357729A1 (en)
WO (1) WO2003043569A2 (en)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8933022B2 (en) 2011-03-01 2015-01-13 Jds Therapeutics, Llc Methods and compositions for the treatment and prevention Hypoglycemia and related disorders
US9005637B2 (en) 2007-06-26 2015-04-14 Jds Therapeutics, Llc Multiple unit dosage form having a therapeutic agent in combination with a nutritional supplement
US9119835B2 (en) 2007-03-13 2015-09-01 JDS Therapeautics, LLC Methods and compositions for the sustained release of chromium

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8754127B2 (en) 2009-02-16 2014-06-17 Nogra Pharma Limited Alkylamido compounds and uses thereof
WO2013117744A2 (en) 2012-02-09 2013-08-15 Nogra Pharma Limited Methods of treating fibrosis
US11865121B2 (en) 2016-02-11 2024-01-09 Nutrition21, LLC Chromium containing compositions for improving health and fitness
EP3419616A1 (en) * 2016-02-26 2019-01-02 Nogra Pharma Limited Methods of treating lactose intolerance
HRP20250208T1 (en) 2019-02-08 2025-04-11 Nogra Pharma Limited METHOD FOR PREPARING 3-(4'-AMINOPHENYL)-2-METHOXYPROPIONIC ACID AND ITS ANALOGUES AND INTERMEDIATES
CN115245510A (en) * 2021-04-28 2022-10-28 扬州大学 Uses of trans-10, cis-12 conjugated linoleic acid

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5948772A (en) * 1998-08-28 1999-09-07 Ambi Inc. Chromium picolinate compositions and uses thereof

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5948772A (en) * 1998-08-28 1999-09-07 Ambi Inc. Chromium picolinate compositions and uses thereof
US6093711A (en) * 1998-08-28 2000-07-25 Ambi Inc. Enteric-coated chromium picolinate compositions and uses thereof

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9119835B2 (en) 2007-03-13 2015-09-01 JDS Therapeautics, LLC Methods and compositions for the sustained release of chromium
US9597404B2 (en) 2007-03-13 2017-03-21 Jds Therapeutics, Llc Methods and compositions for sustained release of chromium
US9005637B2 (en) 2007-06-26 2015-04-14 Jds Therapeutics, Llc Multiple unit dosage form having a therapeutic agent in combination with a nutritional supplement
US9421170B2 (en) 2007-06-26 2016-08-23 Jds Therapeutics, Llc Multiple unit dosage form having a therapeutic agent in combination with a nutritional supplement
US11850308B2 (en) 2007-06-26 2023-12-26 Bonafide Health, Llc Multiple unit dosage form having a therapeutic agent in combination with a nutritional supplement
US8933022B2 (en) 2011-03-01 2015-01-13 Jds Therapeutics, Llc Methods and compositions for the treatment and prevention Hypoglycemia and related disorders

Also Published As

Publication number Publication date
AU2002357729A1 (en) 2003-06-10
AU2002357729A8 (en) 2003-06-10
WO2003043569A2 (en) 2003-05-30

Similar Documents

Publication Publication Date Title
WO2002024180A3 (en) Chromium containing compositions for the treatment of diabetes, the reduction of body fat, improvement of insulin sensitivity and reduction of hyperglycemia and hypercholesteremia
EP1523995A3 (en) Patient-specific dosimetry
PL362687A1 (en) Spaced drug delivery system
NO20003051L (en) Method of administration of AspB28 human insulin
EP1586338A3 (en) The use of antioxidants to prevent oxidation and reduce drug degradation in drug eluting medical devices
SG149814A1 (en) Compositions and methods for treating diabetes
WO1995022965A3 (en) Nasal and ocular administration of ketamine to manage pain and for detoxification
WO2004050115A3 (en) Combination treatment using exendin-4 and thiazolidinediones
WO2003043569A3 (en) Trans-10, cis-12 conjugated linoleic acid isomer for the treatment of diseases
Sicard et al. Local infiltration analgesia versus interscalene nerve block for postoperative pain control after shoulder arthroplasty: a prospective, randomized, comparative noninferiority study involving 99 patients
ATE290863T1 (en) USE OF PROLACTIN MODULATORS AND DIET TO PRODUCE A MEDICATION FOR THE TREATMENT OF OBESITY
HK1079703A1 (en) Method for cardioprotection and neuroprotection by intravenous administration of halogenated volatile anesthetics
WO2003057162A3 (en) Combination for the treatment of immunoinflammatory disorders and proliferative skin diseases
RU2002117537A (en) A method for treating the effects of tissue hypoxia in critically ill patients
Wu et al. Hyperglycemia, hyperlipemia, and periodic paralysis: a case report of new side effects of clozapine
LT2006024A (en) Tetrapeptide regulating blood glucose level in diabetes mellitus
WO2005117937A3 (en) Alpha-1- acid glycoprotein for the treatment of diabetes
WO2004060316A3 (en) Irs modulators
GB0323979D0 (en) Therapeutic applications for c-peptide
WO2006119598A3 (en) Transdermal device for the slow delivery of an omega-3-fatty acid, optionally in combination with a hmg coa reductase inhibitor
Fu et al. A clinical comparative study on effects of intracavernous injection of sodium nitroprusside and papaverine/phentolamine in erectile dysfunction patients
CA3150837A1 (en) Avocatin b for the treatment of diseases and conditions
Gonzalez et al. Growth hormone replacement in patients with hypopituitarism and severe growth hormone deficiency
TW200608965A (en) Medicine for prevention or treatment of diabetes
Booth et al. Factors Associated With Unsafe Needle Injection in Denver

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SC SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR IE IT LU MC NL PT SE SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP

点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载